Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Rhea-AI Summary

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on Tuesday, May 20, 2025, at 5:00 pm EDT in New York. The presentation will be webcast live and available for replay on the company's investor relations website.

News Market Reaction

-2.35%

1 alert

-2.35% News Effect

On the day this news was published, NBTX declined 2.35%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 20, 2025
Time: 5:00 pm EDT / 11:00 pm CEST
Location: New York, NY
Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here

The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com		Investor Relations Department Ricky Bhajun Director, Investor Relations +33 (0)6 42 05 34 15 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachments

• 2025-05-12 -- NBTX -- Presenting @ HCW&Co -- FINAL

FAQ

When is Nanobiotix (NBTX) presenting at the H.C. Wainwright BioConnect Conference 2025?

Nanobiotix will present on Tuesday, May 20, 2025, at 5:00 pm EDT / 11:00 pm CEST in New York, NY.

Who will represent Nanobiotix (NBTX) at the H.C. Wainwright Conference 2025?

Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix, will represent the company at the conference.

What type of company is Nanobiotix (NBTX)?

Nanobiotix is a late-clinical stage biotechnology company that pioneers nanoparticle-based approaches for cancer treatment and other major diseases.

How can investors watch Nanobiotix's (NBTX) presentation at the H.C. Wainwright Conference?

The fireside chat will be webcast live on the events page of the Investors section of Nanobiotix's website, with a replay available after the event.